← Leaderboards
Alexander Kolevzon
Icahn School Of Medicine At Mount Sinai
$6,772,223
Attributed
$6,772,223
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,772,223 · 7
By mechanism
R01$3,654,955 · 1
U54$2,376,055 · 3
R34$740,399 · 1
M01$814 · 2
Top collaborators
No co-investigators on record.
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Yasmin L Hurd$58,238,356
- Anne Christine Gelijns$71,208,615
- Alison M Goate$50,419,418
- Vahram Haroutunian$39,970,462
- Alex D. Federman$23,066,128
Others in their field
Top investigators on “Symptoms”
- Randall J Bateman · Washington University$155,860,406
- Judith S Hochman · New York University School Of Medicine$111,581,511
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$98,224,091
- Eric Martin McDade · Washington University$96,219,353
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
- Monica M Bertagnolli · Strang Cancer Prevention Center$85,994,687
Research focus
SymptomsUnited States National Institutes Of HealthChildGlutamatesScaffolding ProteinPathway InteractionsPlaySynaptic FunctionGenesPostsynapticDensityAutism Spectrum DisorderClinical TrialsCodeBrainBaseElectrophysiology (Science)Biological MarkersNatural HistorySiteIntellectual Functioning DisabilitySensoryPhelan-Mcdermid SyndromeFuture
Grant awards (17)
Clinical trial readiness for targeting neuropsychiatric manifestations in SHANK3 and SYNGAP1 pathogenic variants$579,618
U54 · FY2025 · NS · contact PI
Mapping the Genotype, Phenotype, and Natural History of Phelan McDermid Syndrome$329,862
U54 · FY2023 · NS · contact PI
Electrophysiological Markers for Interventions in Phelan-McDermid Syndrome and Idiopathic Autism$678,016
R01 · FY2022 · NS · contact PI
Mapping the Genotype, Phenotype, and Natural History of Phelan McDermid Syndrome$349,907
U54 · FY2022 · NS · contact PI
Electrophysiological Markers for Interventions in Phelan-McDermid Syndrome and Idiopathic Autism$678,016
R01 · FY2021 · NS · contact PI
Mapping the Genotype, Phenotype, and Natural History of Phelan McDermid Syndrome$353,114
U54 · FY2021 · NS · contact PI
Electrophysiological Markers for Interventions in Phelan-McDermid Syndrome and Idiopathic Autism$841,138
R01 · FY2020 · NS · contact PI
Mapping the Genotype, Phenotype, and Natural History of Phelan McDermid Syndrome$362,878
U54 · FY2020 · NS · contact PI
Electrophysiological Markers for Interventions in Phelan-McDermid Syndrome and Idiopathic Autism$648,380
R01 · FY2019 · NS · contact PI
Mapping the Genotype, Phenotype, and Natural History of Phelan McDermid Syndrome$400,676
U54 · FY2019 · NS · contact PI
Electrophysiological Markers for Interventions in Phelan-McDermid Syndrome and Idiopathic Autism$161,025
R01 · FY2019 · NS · contact PI
Electrophysiological Markers for Interventions in Phelan-McDermid Syndrome and Idiopathic Autism$648,380
R01 · FY2018 · NS · contact PI
Piloting Treatment with Insulin-Like Growth Factor-1 in Phelan-McDermid Syndrome$84,750
R34 · FY2015 · MH · contact PI
Piloting Treatment with Insulin-Like Growth Factor-1 in Phelan-McDermid Syndrome$289,286
R34 · FY2014 · MH · contact PI
Piloting Treatment with Insulin-Like Growth Factor-1 in Phelan-McDermid Syndrome$366,363
R34 · FY2013 · MH · contact PI
OPEN LABEL RISPERIDONE IN CHILDREN AND ADOLESCENTS WITH AUTISTIC DISORDER$244
M01 · FY2009 · RR · contact PI
EFFECT OF FLUOXETINE ORALLY DISSOLVING TABLET (ODT) ON REPETITIVE BEHAVIORS$570
M01 · FY2008 · RR · contact PI